TISSIUM CEO’s Vision Is To Make The Tissue Recon Label Stick
CEO Bancel Envisages TISSIUM As A Tissue Reconstruction Specialist Rather Than Simply A Provider Of A Technology
Executive Summary
Christophe Bancel, CEO of French medtech innovator TISSIUM, has made a career in various parts of the health care products industry, identifying business opportunities, founding, directing and leading ventures, and planning for contingencies. The ex-Serono and UCB executive, who has had many other postings, is now testing his adaptability and leadership qualities by bringing a versatile class III synthetic polymer device into key markets.
You may also be interested in...
Solventum: The Identity Of 3M’s Health Care Spin-Off
3M’s health care company spin-off is expected to be launched in the first half of 2024 under the name Solventum.
Manufacturing Devices In The Rollercoaster UK Market
A scale-up strategy is the missing link in the UK devices industry, claims business research organization CPI. Own brand and contract medical manufacturer and packaging company Pennine Healthcare and longstanding medical device CDMO Renfrew Group International give their take on the environment for manufacturers and the opportunities for strengthening the industry base.
Innovation Adoption: ‘Medtech’s Ongoing Challenge Of The Day’
UK ministers are increasingly focusing on the need to improve uptake of new technologies in the National Health Service. Ambitious programs have been launched but implementing them effectively for lasting change in a delivery system under acute stress is a challenge of a different order.